GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Net Income Including Noncontrolling Interests

VRCDF (Verici Dx) Net Income Including Noncontrolling Interests : $-5.87 Mil (TTM As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Verici Dx's Net Income Including Noncontrolling Interests for the six months ended in Dec. 2024 was $-4.53 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2024 was $-5.87 Mil.

Verici Dx Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Verici Dx's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Net Income Including Noncontrolling Interests Chart

Verici Dx Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Net Income Including Noncontrolling Interests
- -8.33 -11.41 -8.73 -5.87

Verici Dx Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only -5.94 -5.27 -3.46 -1.35 -4.53

Verici Dx Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-5.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Verici Dx Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Verici Dx's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Verici Dx Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
LSE:GENI LSE:OBD LSE:GDR LSE:PRM LSE:ABDX TSE:2397 TMO DHR XSWX:LONN IDXX A IQV SHSE:603259 MTD NTRA LH WAT DGX XPAR:BIM ILMN
Traded in Other Exchanges
VRCI:UK 63V:Germany
Address
19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ
Website
https://www.vericidx.com
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx Headlines

No Headlines